{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:40:38Z","timestamp":1772214038436,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.actbio.2017.02.040","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T03:05:49Z","timestamp":1487905549000},"page":"419-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Antiresorptive and anti-angiogenetic octacalcium phosphate functionalized with bisphosphonates: An in vitro tri-culture study"],"prefix":"10.1016","volume":"54","author":[{"given":"Lucia","family":"Forte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Torricelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3754-0273","authenticated-orcid":false,"given":"Elisa","family":"Boanini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Gazzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Fini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Bigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2017.02.040_b0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.actbio.2017.02.040_b0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","article-title":"Bisphosphonates in cancer therapy","volume":"257","author":"Stresing","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.actbio.2017.02.040_b0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence onclinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.actbio.2017.02.040_b0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2010.09.035","article-title":"Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase","volume":"48","author":"Stresing","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.actbio.2017.02.040_b0025","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2017.02.040_b0030","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbrc.2007.01.014","article-title":"Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells","volume":"354","author":"Hashimoto","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.actbio.2017.02.040_b0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1538-7836.2006.02259.x","article-title":"Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation dependent signaling pathways","volume":"5","author":"Hasmim","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.actbio.2017.02.040_b0040","doi-asserted-by":"crossref","first-page":"43603","DOI":"10.1074\/jbc.M308114200","article-title":"Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B\/Akt","volume":"278","author":"Bezzi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.actbio.2017.02.040_b0045","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1590\/S0004-27302006000400018","article-title":"Bisphosphonates","volume":"50","author":"McClung","year":"2006","journal-title":"Arq. Bras. Endocrinol. Metabol."},{"key":"10.1016\/j.actbio.2017.02.040_b0050","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bone.2009.05.008","article-title":"Histologic and histomorphometric featuresof bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy","volume":"45","author":"Favia","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.actbio.2017.02.040_b0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","article-title":"Subtrochanteric fractures after long-term treatment with bisphosphonates: a European society on clinical and economic aspects ofosteoporosis and osteoarthritis, and international osteoporosis foundation working group report","volume":"22","author":"Rizzoli","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.actbio.2017.02.040_b0060","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.drudis.2013.08.010","article-title":"Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?","volume":"19","author":"Verron","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.actbio.2017.02.040_b0065","doi-asserted-by":"crossref","first-page":"547552","DOI":"10.1016\/j.drudis.2010.05.003","article-title":"Calcium phosphate biomaterials as bone drug delivery systems: a review","volume":"15","author":"Verron","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.actbio.2017.02.040_b0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.actbio.2014.09.006","article-title":"Local drug delivery for enhancing fracture healing in osteoporotic bone","volume":"11","author":"Kyll\u00f6nen","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2017.02.040_b0075","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1016\/j.actbio.2014.07.012","article-title":"Vertebroplasty using bisphosphonate-loaded calcium phosphate cement in a standardized vertebral body bone defect in an osteoporotic sheep model","volume":"10","author":"Verron","year":"2014","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2017.02.040_b0080","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jinorgbio.2010.06.008","article-title":"Functionalization of biomimetic calcium phosphate bone cements with alendronate","volume":"104","author":"Panzavolta","year":"2010","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.actbio.2017.02.040_b0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.colsurfb.2015.09.044","article-title":"Antiresorption implant coatings based on calcium alendronate and octacalcium phosphate deposited by matrix assisted pulsed laser evaporation","volume":"136","author":"Boanini","year":"2015","journal-title":"Colloids Surf., B"},{"key":"10.1016\/j.actbio.2017.02.040_b0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcis.2014.01.017","article-title":"Infrared, Raman and NMR investigations of risedronate adsorption on nanocrystalline apatites","volume":"420","author":"Errassifi","year":"2014","journal-title":"J. Colloid Interf. Sci."},{"key":"10.1016\/j.actbio.2017.02.040_b0095","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.biomaterials.2011.09.092","article-title":"The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells in vitro","volume":"33","author":"Boanini","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2017.02.040_b0100","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/adma.200602497","article-title":"Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure","volume":"19","author":"Boanini","year":"2007","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2017.02.040_b0105","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1134\/S2075113310030019","article-title":"Osteoinductive ceramic materials for bone tissue restoration: Octacalcium phosphate (review)","volume":"1","author":"Barinov","year":"2010","journal-title":"Inorg. Mater. Appl. Res."},{"key":"10.1016\/j.actbio.2017.02.040_b0110","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.biomaterials.2005.12.004","article-title":"Bone formation enhanced by implanted octacalcium phosphate involving conversion into Ca-deficient hydroxyapatite","volume":"27","author":"Suzuki","year":"2006","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2017.02.040_b0115","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/j.actbio.2010.04.002","article-title":"Octacalcium phosphate: osteoconductivity and crystal chemistry","volume":"6","author":"Suzuki","year":"2010","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2017.02.040_b0120","doi-asserted-by":"crossref","first-page":"22602","DOI":"10.1021\/am5067139","article-title":"Osteoconductive property of a mechanical mixture of octacalcium phosphate and amorphous calcium phosphate","volume":"6","author":"Kobayashi","year":"2014","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2017.02.040_b0125","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/1961048b0","article-title":"Octacalcium phosphate and hydroxyapatite: crystallographic and chemical relations between octacalcium phosphate and hydroxyapatite","volume":"196","author":"Brown","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2017.02.040_b0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01194315","article-title":"Crystal structure of octacalciumbis(hydrogenphosphate) tetrakis(phosphate) pentahydrate, Ca8(HPO4)4\u00b75H2O","volume":"18","author":"Mathew","year":"1988","journal-title":"Cryst. Spectrosc. Res."},{"key":"10.1016\/j.actbio.2017.02.040_b0135","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0731-7085(02)00021-3","article-title":"Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions","volume":"28","author":"Kuljanin","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.actbio.2017.02.040_b0140","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1002\/adma.201301129","article-title":"Crystalline calcium alendronate obtained by octacalcium phosphate digestion: a new chance for local treatment of bone loss diseases?","volume":"25","author":"Boanini","year":"2013","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2017.02.040_b0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/jcis.2001.8026","article-title":"Effect of electrostatic interaction on the adsorption of globular proteins on octacalcium phosphate crystal film","volume":"246","author":"Lee","year":"2002","journal-title":"J. Colloid Interf. Sci."},{"key":"10.1016\/j.actbio.2017.02.040_b0150","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1039\/c2cc17635a","article-title":"Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers","volume":"48","author":"Liu","year":"2012","journal-title":"Polym. Chem. Commun."},{"key":"10.1016\/j.actbio.2017.02.040_b0155","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1021\/jp304472s","article-title":"Time course of zoledronate interaction with hydroxyapatite nanocrystals","volume":"116","author":"Boanini","year":"2012","journal-title":"J. Phys. Chem. C"},{"key":"10.1016\/j.actbio.2017.02.040_b0160","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.actbio.2017.02.040_b0165","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1021\/cg100494f","article-title":"Collapsed Octacalcium phosphate stabilized by ionic substitutions","volume":"10","author":"Boanini","year":"2010","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.actbio.2017.02.040_b0170","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/adhm.201600184","article-title":"The effects of crystal phase and particle morphology of calcium phosphates on proliferation and differentiation of human mesenchymal stromal cells","volume":"5","author":"Danoux","year":"2016","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.actbio.2017.02.040_b0175","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.bone.2012.07.020","article-title":"The effect of alendronate doped calcium phosphates on bone cells activity","volume":"51","author":"Boanini","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.actbio.2017.02.040_b0180","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.coph.2005.06.005","article-title":"Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength","volume":"6","author":"Kostenuik","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.actbio.2017.02.040_b0185","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1016\/j.biomaterials.2014.03.053","article-title":"Combined effect of strontium and zoledronate on hydroxyapatite structure and bone cell responses","volume":"35","author":"Boanini","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2017.02.040_b0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","article-title":"Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro","volume":"15","author":"Ziebart","year":"2011","journal-title":"Clin. Oral Investig."},{"key":"10.1016\/j.actbio.2017.02.040_b0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jcmm.12154","article-title":"Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells","volume":"18","author":"Ribeiro","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.actbio.2017.02.040_b0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1756-8722-5-56","article-title":"Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw","volume":"5","author":"Vincenzi","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2017.02.040_b0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12032-008-9043-5","article-title":"Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases","volume":"25","author":"Tas","year":"2008","journal-title":"Med. Oncol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706117301460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706117301460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:53:43Z","timestamp":1761670423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706117301460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":41,"alternative-id":["S1742706117301460"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2017.02.040","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiresorptive and anti-angiogenetic octacalcium phosphate functionalized with bisphosphonates: An in vitro tri-culture study","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2017.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}